Company profile: Phio Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of RNAi immuno-oncology therapies leveraging the INTASYL self-delivering RNAi platform to create siRNA compounds that silence gene targets. Pipeline includes PH-762 (intratumoral PD-1 silencing for cSCC, melanoma, Merkel cell carcinoma), PH-894 (intratumoral BRD4 silencing for advanced melanoma and other cancers), and PH-762 + adoptive cell therapy with double positive CD8 Tils (IV for stage IV melanoma and solid tumors).
Products and services
- PH-762: An intratumoral INTASYL RNAi product that silences the PD-1 protein, administered directly into tumors to treat various stages of cSCC, melanoma, and Merkel cell carcinoma
- INTASYL: A self-delivering RNAi platform for immuno-oncology that enables creation of siRNA compounds to silence gene targets
- PH-894: An intratumoral RNAi product that targets and silences the BRD4 protein, delivered into tumors for treating advanced melanoma and other cancers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Phio Pharmaceuticals
Neurogene
HQ: United States
Website
- Description: Provider of genetic medicines for neurological disorders, offering EXACT gene therapy technology for controlled and balanced gene expression, a platform that delivers consistent transgene expression (utilized in Rett syndrome) with CNS and ocular delivery, robust CGMP-compliant internal manufacturing for research and clinical material, and clinical trials to evaluate safety and efficacy in genetic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurogene company profile →
Spark Therapeutics
HQ: United States
Website
- Description: Provider of potentially curative, one-time gene therapy treatments for genetic diseases, including investigational programs such as SPK-8011 for hemophilia A, fidanacogene elaparvovec (SPK-9001) for hemophilia B, SPK-3006 for Pompe disease, and gene therapies targeting Stargardt and Huntington’s diseases, plus AAV-based research programs for the retina, liver, and central nervous system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spark Therapeutics company profile →
ReNAgade Therapeutics
HQ: United States
Website
- Description: Provider of RNA therapeutic platforms, offering RNA delivery systems to target previously inaccessible cells, an RNA coding platform (with Orna Therapeutics) for reprogramming cells, proprietary gene editing technology for permanent gene correction, and an all-RNA Gene Therapy 2.0 platform enabling exon and large gene insertions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ReNAgade Therapeutics company profile →
Beam Therapeutics
HQ: United States
Website
- Description: Provider of precision genetic medicines using base editing, including BEAM-101 for sickle cell disease; BEAM-201, an anti-CD7 CAR-T for relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; and liver-targeting LNPs BEAM-301 and BEAM-302 to correct the R83C mutation in Glycogen Storage Disease Type 1a and the PiZ allele in severe Alpha-1 antitrypsin deficiency, plus base editing delivery technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Beam Therapeutics company profile →
Kate Therapeutics
HQ: United States
Website
- Description: Provider of AAV-based gene therapies targeting genetically defined muscle and heart diseases, supported by the DELIVER capsid engineering platform for evolving tissue-targeted AAV variants, MyoAAV muscle-tropic capsids for skeletal and cardiac delivery, and cargo technologies to enhance regulation, targeting, and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kate Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Phio Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Phio Pharmaceuticals
2.2 - Growth funds investing in similar companies to Phio Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Phio Pharmaceuticals
4.2 - Public trading comparable groups for Phio Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →